Sinovac Biotech Ltd
SVA0.000
Close 12/08, 16:00（ET）Quotes delayed by 15 min
--Market Cap
--P/E TTM
More Details of Sinovac Biotech Ltd Company
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
Sinovac Biotech Ltd Info
Ticker SymbolSVA
Company nameSinovac Biotech Ltd
IPO dateNov 13, 2009
CEOYin (Weidong)
Number of employees3037
Security typeOrdinary Share
Fiscal year-endNov 13
AddressNo. 39 Shangdi Xi Road
CityBEIJING
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryChina
Postal code100085
Phone861082890088
Websitehttp://www.sinovac.com/
Ticker SymbolSVA
IPO dateNov 13, 2009
CEOYin (Weidong)
Company Executives of Sinovac Biotech Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Weidong Yin
Mr. Weidong Yin
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
6.36M
--
Mr. Qiang Gao
Mr. Qiang Gao
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Chiang Li
Dr. Chiang Li
Independent Director
Independent Director
--
--
Ms. Guang (Helen) Yang
Ms. Guang (Helen) Yang
Chief Business Officer
Chief Business Officer
--
--
Ms. Nan Wang
Ms. Nan Wang
Chief Financial Officer, Vice President
Chief Financial Officer, Vice President
--
--
Prof. Yuk Lam Lo
Prof. Yuk Lam Lo
Independent Director
Independent Director
--
--
Ms. Jing Li
Ms. Jing Li
Vice President - Quality and Production
Vice President - Quality and Production
--
--
Mr. Simon J. Anderson
Mr. Simon J. Anderson
Director
Director
--
--
Mr. Shan Fu
Mr. Shan Fu
Director
Director
--
--
Ms. Rui-Ping Xiao
Ms. Rui-Ping Xiao
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Weidong Yin
Mr. Weidong Yin
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
6.36M
--
Mr. Qiang Gao
Mr. Qiang Gao
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Chiang Li
Dr. Chiang Li
Independent Director
Independent Director
--
--
Ms. Guang (Helen) Yang
Ms. Guang (Helen) Yang
Chief Business Officer
Chief Business Officer
--
--
Ms. Nan Wang
Ms. Nan Wang
Chief Financial Officer, Vice President
Chief Financial Officer, Vice President
--
--
Prof. Yuk Lam Lo
Prof. Yuk Lam Lo
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Mainland China
381.06M
85.01%
Foreign countries
67.21M
14.99%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
1Globe Capital, L.L.C.
20.84%
SAIF Advisors Limited
17.95%
Yin (Weidong)
10.59%
CDH Utopia Ltd
9.99%
Vivo Capital, LLC
9.83%
Other
30.81%
Shareholders
Shareholders
Proportion
1Globe Capital, L.L.C.
20.84%
SAIF Advisors Limited
17.95%
Yin (Weidong)
10.59%
CDH Utopia Ltd
9.99%
Vivo Capital, LLC
9.83%
Other
30.81%
Shareholder Types
Shareholders
Proportion
Corporation
40.57%
Private Equity
22.48%
Individual Investor
10.59%
Venture Capital
9.83%
Hedge Fund
2.23%
Investment Advisor
0.64%
Pension Fund
0.11%
Investment Advisor/Hedge Fund
0.07%
Research Firm
0.04%
Other
13.44%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
44
21.27M
35.41%
+1.17M
2025Q2
44
50.49M
80.19%
+7.31M
2025Q1
43
41.31M
49.65%
+4.02M
2024Q4
43
35.46M
35.59%
-13.70M
2024Q3
45
47.33M
47.51%
-1.85M
2024Q2
45
48.79M
48.97%
+2.33M
2024Q1
45
46.23M
46.40%
+10.46M
2023Q4
44
35.53M
35.68%
-8.81M
2023Q3
46
44.32M
44.54%
-16.57K
2023Q2
46
44.32M
44.54%
+2.81M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
1Globe Capital, L.L.C.
12.52M
20.84%
--
--
Jul 07, 2025
SAIF Advisors Limited
10.78M
17.95%
--
--
Jul 10, 2025
Yin (Weidong)
6.36M
10.59%
--
--
Jul 10, 2025
CDH Utopia Ltd
6.00M
9.99%
--
--
Jul 07, 2025
Vivo Capital, LLC
5.90M
9.83%
--
--
Jul 11, 2025
Advantech Capital LP
5.85M
9.74%
--
--
Jul 08, 2025
OrbiMed Advisors, LLC
2.72M
4.53%
--
--
Jun 30, 2025
Renaissance Technologies LLC
1.31M
2.19%
+1.31M
--
Jun 30, 2025
Neumann Advisory Hong Kong Limited
315.59K
0.53%
--
--
Jun 30, 2025
California Public Employees' Retirement System
68.73K
0.11%
+68.73K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
SPDR SSGA US Small Cap Low Volatility Index ETF
0%
SPDR S&P Emerging Markets Small Cap ETF
0%
SPDR Portfolio Emerging Markets ETF
0%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proportion0%
SPDR S&P Emerging Markets Small Cap ETF
Proportion0%
SPDR Portfolio Emerging Markets ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Sinovac Biotech Ltd?
The top five shareholders of Sinovac Biotech Ltd are:
1Globe Capital, L.L.C. holds 12.52M shares, accounting for 20.84% of the total shares.
SAIF Advisors Limited holds 10.78M shares, accounting for 17.95% of the total shares.
Yin (Weidong) holds 6.36M shares, accounting for 10.59% of the total shares.
CDH Utopia Ltd holds 6.00M shares, accounting for 9.99% of the total shares.
Vivo Capital, LLC holds 5.90M shares, accounting for 9.83% of the total shares.
1Globe Capital, L.L.C. holds 12.52M shares, accounting for 20.84% of the total shares.
SAIF Advisors Limited holds 10.78M shares, accounting for 17.95% of the total shares.
Yin (Weidong) holds 6.36M shares, accounting for 10.59% of the total shares.
CDH Utopia Ltd holds 6.00M shares, accounting for 9.99% of the total shares.
Vivo Capital, LLC holds 5.90M shares, accounting for 9.83% of the total shares.
What are the top three shareholder types of Sinovac Biotech Ltd?
The top three shareholder types of Sinovac Biotech Ltd are:
1Globe Capital, L.L.C.
SAIF Advisors Limited
Yin (Weidong)
1Globe Capital, L.L.C.
SAIF Advisors Limited
Yin (Weidong)
How many institutions hold shares of Sinovac Biotech Ltd (SVA)?
As of 2025Q3, 44 institutions hold shares of Sinovac Biotech Ltd, with a combined market value of approximately 21.27M, accounting for 35.41% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -44.78%.
What is the biggest source of revenue for Sinovac Biotech Ltd?
In FY2023, the -- business generated the highest revenue for Sinovac Biotech Ltd, amounting to -- and accounting for --% of total revenue.
